Gilead Sciences, Inc.
Clinical trials sponsored by Gilead Sciences, Inc., explained in plain language.
A biopharmaceutical company developing antiviral and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a new pill help kids fight hepatitis b? Results expected Sep 2026 (estimated)
- New drug combo targets tough tumors Results expected Oct 2026 (estimated)
- New drug shows promise against tough cancers Results expected Oct 2026 (estimated)
- New pill for weight loss enters human testing Results expected Nov 2026 (estimated)
- New study seeks safe dose of cancer drug for patients with liver issues Results expected Dec 2026 (estimated)
-
New pill takes aim at stubborn blood sugar
Disease control Stopped earlyResearchers are testing an experimental oral drug called MBX-102 in adults with type 2 diabetes whose blood sugar remains too high on metformin alone. The trial compares two doses of MBX-102 with a placebo and with Actos, an approved diabetes drug. About 242 participants take the…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug bulevirtide tracked in real-world hepatitis d patients
Disease control Stopped earlyThis study follows 170 people with chronic hepatitis D who are taking bulevirtide to see how well it works over time and what side effects may occur. Researchers will track serious liver problems like liver failure, cancer, or need for transplant. The goal is to understand the dr…
Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug candidate enters early human testing
Disease control Stopped earlyThis early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safet…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple pill tame RSV? new trial tests obeldesivir
Disease control Stopped earlyThis phase 2 study tests whether an oral antiviral pill called obeldesivir can safely shorten RSV symptoms in adults who are not hospitalized but are at higher risk for severe disease (e.g., those aged 60+ or with chronic lung conditions). Participants take the pill or a placebo,…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Rheumatoid arthritis drug study halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Weekly HIV pill shows promise but study halted early
Disease control Stopped earlyThis study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…
Phase 2/3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Lupus skin drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Cancer drug combo trial halted early – what we know
Disease control Stopped earlyThis study tested a drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early, so results are limited.
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising combo for tough breast cancer hits snag: trial ends early
Disease control Stopped earlyThis study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was terminated earl…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New HIV drug candidate GS-1219 tested in tiny early trial
Disease control Stopped earlyThis was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New HIV prevention pill shows promise in large trial
Prevention Stopped earlyThis phase 3 study tested a daily pill called F/TAF (Descovy) to prevent HIV infection in nearly 5,400 men and transgender women who have sex with men and are at high risk. Participants took either F/TAF or the existing prevention drug Truvada. The goal was to see if F/TAF is as …
Phase 3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
RSV drug trial for kids under 5 halted early – only 4 children enrolled
Symptom relief Stopped earlyThis study tested an oral antiviral drug called obeldesivir in children from birth to under 5 years old who had RSV infection. The goal was to see if the drug is safe and helps reduce symptoms faster. However, the trial was stopped early and only enrolled 4 participants, so the r…
Phase 2 • Sponsor: Gilead Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC